Madrigal’s Maestro result puts the focus on Nash
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
As Forte fails, who might yet improve the image of reverse mergers?
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The dream is over for Intercept
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
Novo’s Nash play takes shape
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
